Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme (12 selected)

Guidance programme

Showing 1 to 25 of 888

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Sinusitis (acute): antimicrobial prescribingNG79
Cataracts in adults: managementNG77
Cystic fibrosis: diagnosis and managementNG78
Hepatitis B (chronic): diagnosis and managementCG165
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Child maltreatment: when to suspect maltreatment in under 18sCG89
Child abuse and neglectNG76
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478
Reslizumab for treating severe eosinophilic asthmaTA479
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone diseaseIPG593
Faltering growth: recognition and management of faltering growth in childrenNG75
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Intermediate care including reablementNG74
Type 2 diabetes: prevention in people at high riskPH38
Ab externo canaloplasty for primary open-angle glaucomaIPG591
High-intensity focused ultrasound for symptomatic breast fibroadenomaIPG592
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Fertility problems: assessment and treatmentCG156
Sorafenib for treating advanced hepatocellular carcinomaTA474
Dimethyl fumarate for treating moderate to severe plaque psoriasisTA475

Results per page

  1. 10
  2. 25
  3. 50
  4. All